Mode
Text Size
Log in / Sign up

Meta-analysis finds depression associated with elevated Parkinson's disease risk

Meta-analysis finds depression associated with elevated Parkinson's disease risk
Photo by runda choo / Unsplash
Key Takeaway
Consider depression as a potential risk marker, not cause, for Parkinson's disease based on observational association.

This meta-analysis and systematic review examined the association between depression and subsequent Parkinson's disease development, analyzing 39 studies in the first review and 3 studies in the second. The population included patients with Parkinson's disease reporting prior depression, depressed patients who developed Parkinson's disease, and patients with late-onset depression. The exposure was depression, with no specific comparator reported.

For the association between depression and subsequent Parkinson's disease, retrospective studies showed an odds ratio of 2.17 (95% CI: 1.92-2.46), while prospective studies showed an odds ratio of 2.01 (95% CI: 1.20-3.38). In late-onset depression patients, dopamine transporter imaging revealed dopaminergic deficits in 24%-79% of patients. No safety or tolerability data were reported.

Key limitations include that none of the 39 studies in the first review examined neurobiological data, and no studies in late-onset depression patients determined α-synuclein. The authors note that longitudinal studies in late-onset depression patients are essential to establish neurobiological evidence that depression might be an early manifestation of an α-synucleinopathy like Parkinson's disease. The findings represent association, not causation, and come from observational studies.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Parkinson's disease (PD) is characterized by two neurobiological markers: pathological α-synuclein and/or a dopaminergic deficit. Depression is common in PD, and may precede motor signs, particularly in late-onset depression (LOD). We conducted two systematic reviews and a meta-analysis to examine the relationship between depression and PD development. First, we evaluated whether depression is associated with an increased risk of developing PD, and whether pathological α-synuclein or dopaminergic deficits were observed in depressed patients prior to PD diagnosis. Second, we evaluated whether studies examined neurobiological markers in LOD patients, regardless of subsequent PD development. Our first review identified 39 studies showing a positive association between depression and subsequent PD. This was supported by an exploratory meta-analysis, stratified by index condition: 1) retrospective studies of patients with PD reporting prior depression (odds ratio [OR] = 2.17, 95% CI: 1.92-2.46) and 2) prospective studies of depressed patients who developed PD (OR = 2.01, 95% CI: 1.20-3.38). Importantly, none of these studies examined neurobiological data. Our second review identified three cross-sectional studies reporting that 24%-79% of the LOD patients had a dopaminergic deficit as detected by dopamine transporter (DAT) imaging. We found no studies in LOD in which α-synuclein was determined. Given the observed moderately elevated risk for developing PD in depressed patients, the high incidence of abnormal DAT scans in LOD, and ageing as a major risk factor for developing PD, longitudinal studies in LOD patients are essential to establish neurobiological evidence that depression can be an early manifestation of an α-synucleinopathy like PD.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.